SIMCERE PHARMA (02096) announced on December 7, 2025, that Enzastaurin® (Suvizumab for Injection) has been officially included in the updated National Reimbursement Drug List (NRDL) issued by China's National Healthcare Security Administration and Ministry of Human Resources and Social Security. The inclusion will take effect from January 1, 2026. Additionally, Endostar® (Recombinant Human Endostatin Injection) has successfully completed its renewal in the NRDL.

Enzastaurin® is a next-generation recombinant humanized anti-vascular endothelial growth factor (VEGF) monoclonal antibody, approved for marketing in China on June 30, 2025. It is indicated in combination with paclitaxel, liposomal doxorubicin, or topotecan for the treatment of adult patients with recurrent ovarian, fallopian tube, or primary peritoneal cancer who have developed platinum resistance and received no more than one prior systemic therapy.

Endostar®, China's first anti-angiogenic targeted drug and the world's only approved endostatin product, has been included in the NRDL since 2017. It has become one of the cornerstone treatments for advanced non-small cell lung cancer.